PE20090515A1 - Nuevo procedimiento de preparacion - Google Patents

Nuevo procedimiento de preparacion

Info

Publication number
PE20090515A1
PE20090515A1 PE2008001363A PE2008001363A PE20090515A1 PE 20090515 A1 PE20090515 A1 PE 20090515A1 PE 2008001363 A PE2008001363 A PE 2008001363A PE 2008001363 A PE2008001363 A PE 2008001363A PE 20090515 A1 PE20090515 A1 PE 20090515A1
Authority
PE
Peru
Prior art keywords
compound
ilo
alkyl
cgrp
preparation procedure
Prior art date
Application number
PE2008001363A
Other languages
English (en)
Inventor
Juergen Schnaubelt
Michael Konrad
Thomas Krueger
Joern Merten
Rolf Schmid
Emanuel Stehle
Thomas Fachinger
Carsten Reichel
Svenja Renner
Bianca Werner
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20090515A1 publication Critical patent/PE20090515A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/96—Esters of carbonic or haloformic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

REFERIDA UN PROCEDIMIENTO PARA PREPARAR COMPUESTOS DE FORMULA (I): DONDE R1 ES H, ALQUILO (C1-C3), C(O)-O-BENCILO, ENTRE OTROS; R2 ES AMINA SECUNDARIA -NR2.1R2.2-; R2,1 Y R2.2 SON CADA UNO ALQUILO (C1-C3), MORFOLIN-4-ILO, 1-METILPIPERAZIN-4-ILO, 1-BENCILPIPERAZIN-4-ILO, ENTRE OTROS, QUE COMPRENDE: (a) REACCION OR3-CO-CH3-OH EN PRESENCIA DE UN ACIDO Y DISOLVENTE APROTICO PARA DAR SU CORRESPONDIENTE ESTER, DONDE R3 ES ALQUILO (C1-C6); (b) MEZCLA DEL ESTER, CON UN COMPUESTO (IV), DONDE R1 ES COMO SE DEFINIO; (c) MEZCLA DEL PRODUCTO OBTENIDO CON UNA BASE FUERTE TAL COMO KOH; (d) RECRISTALIZACION DEL COMPUESTO, POSTERIOR REDUCCION Y AISLAMIENTO DE DICHO COMPUESTO. UN COMPUESTO OBTENIDO ES (3Z)-3-(4-BENCILOXI-3,5-DIMETIL-FENIL)-2-TETRAHIDROPIRAN-2-ILOXI)-ACRILICO. DICHOS COMPUESTOS SON ANTAGONISTAS DE CGRP Y SON UTILES EN EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA EXPRESION DEL GEN CGRP
PE2008001363A 2007-08-13 2008-08-11 Nuevo procedimiento de preparacion PE20090515A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007038251A DE102007038251A1 (de) 2007-08-13 2007-08-13 Neues Herstellverfahren

Publications (1)

Publication Number Publication Date
PE20090515A1 true PE20090515A1 (es) 2009-05-28

Family

ID=39874112

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001363A PE20090515A1 (es) 2007-08-13 2008-08-11 Nuevo procedimiento de preparacion

Country Status (16)

Country Link
US (1) US8288531B2 (es)
EP (1) EP2188275A2 (es)
JP (1) JP2010535838A (es)
KR (1) KR20100052531A (es)
CN (1) CN101821258A (es)
AR (1) AR068807A1 (es)
AU (1) AU2008288430A1 (es)
BR (1) BRPI0815419A2 (es)
CA (1) CA2696257A1 (es)
CL (1) CL2008002377A1 (es)
DE (1) DE102007038251A1 (es)
MX (1) MX2010001512A (es)
PE (1) PE20090515A1 (es)
TW (1) TW200918518A (es)
UY (1) UY31282A1 (es)
WO (1) WO2009021943A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007038250A1 (de) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neues Herstellverfahren
CN103601722B (zh) * 2013-09-13 2016-03-02 南京华威医药科技开发有限公司 新型抗肿瘤化合物
CN105777615A (zh) * 2016-04-07 2016-07-20 戊言医药科技（上海）有限公司 4-吗啉代哌啶的制备方法
US10835535B2 (en) 2016-05-07 2020-11-17 Shanghai Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
CN109311811B (zh) * 2016-06-09 2022-09-09 有机合成药品工业株式会社 4-(哌啶-4-基)吗啉的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904421D0 (sv) * 1999-12-03 1999-12-03 Astra Ab New compounds
DK1537091T3 (da) * 2002-08-30 2010-11-08 Hoffmann La Roche Hidtil ukendte 2-arylthiazolforbindelser som PPAR alpha- og PPAR gamma-agonister
EP1619187A1 (de) 2004-07-23 2006-01-25 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von 3-(4-Piperidinyl)- 2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-on
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1770086A1 (de) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102005061472A1 (de) 2005-12-22 2007-07-05 Saltigo Gmbh Verfahren zur Herstellung von enantiomerenangereicherten 2-Alkoxy-3-phenylpropionsäuren

Also Published As

Publication number Publication date
AR068807A1 (es) 2009-12-09
US8288531B2 (en) 2012-10-16
BRPI0815419A2 (pt) 2015-02-03
DE102007038251A1 (de) 2009-02-19
TW200918518A (en) 2009-05-01
MX2010001512A (es) 2010-03-10
KR20100052531A (ko) 2010-05-19
WO2009021943A2 (de) 2009-02-19
UY31282A1 (es) 2009-03-31
CL2008002377A1 (es) 2009-10-23
WO2009021943A3 (de) 2009-04-30
AU2008288430A1 (en) 2009-02-19
CA2696257A1 (en) 2009-02-19
JP2010535838A (ja) 2010-11-25
EP2188275A2 (de) 2010-05-26
US20110087021A1 (en) 2011-04-14
CN101821258A (zh) 2010-09-01

Similar Documents

Publication Publication Date Title
CL2011003072A1 (es) Compuestos derivados de 4´-(isoxazol-5-il)-bifenil-4-il-cicloalquil(c3-8), antagonistas del receptor de acido lisofosfatidico; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, problemas pulmonares, entre otras.
PE20200401A1 (es) Nuevos compuestos como inhibidores de autotaxina y composiciones farmaceuticas que comprenden a los mismos
DOP2009000148A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
CO6311106A2 (es) Derivados novedosos del acido oleanólico con saturacion del anillo c
PE20090515A1 (es) Nuevo procedimiento de preparacion
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR070828A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
PE20141726A1 (es) Heterociclilaminas como inhibidores de pi 3k
AR060489A1 (es) Derivados del acido benzoazepin - oxi- acetico como agonistas de ppar - delta usados para aumentar hdl- c, reducir ldl-c y reducir colesterol
AR074676A1 (es) Derivados de isooxazol como antagonistas de receptores de acido lisofosfatidico, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la actividad fisiologica de lpa.
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
UY31796A (es) Derivados de ácido ciclopentanocarboxílico condensados sustituidos con acilamino y su uso como productos farmacéuticos.
UY31831A (es) Derivados de indazoles sustituidos con fenilo o piridinilo
PE20090892A1 (es) MODULADORES DUALES DE LOS RECEPTORES 5-HT2a Y D3
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
DOP2013000191A (es) Derivados de heteroarilo como modulares de nachr alfa 7
PE20100487A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
EA023861B3 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
PE20140966A1 (es) Quinazolincarboxamida azetidinas
PE20061446A1 (es) Compuestos de bencimidazol-carboxamida como agonistas de receptores 5-ht4
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
MX2013008531A (es) Nuevos compuestos de benzodioxol-piperazina.
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
CL2010000253A1 (es) Procedimiento de preparacion de ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable; y uno de los compuestos intermediarios considerados.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal